Stay updated with breaking news from Bernhard Hemmer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A novel biosimilar matches natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing remitting multiple sclerosis, results from a new phase 3 trial show.
The Zentrum für Digitale Medizin und Gesundheit (ZDMG) will bring together researchers in medicine, informatics and mathematics. They will collaborate on new healthcare developments based on data science and artificial intelligence and pursue clinica